These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31888399)

  • 1. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.
    Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L
    J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials.
    Elbadawi A; Shnoda M; Mahmoud K; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):380-388. PubMed ID: 32556105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
    Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
    Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
    Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
    Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
    JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
    Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
    J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
    Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P; Bilen MA; Gao X; Heng D; Pal S; Narra R; Kilari D; Kaymakcalan MD; McGregor B; Choueiri TK; McKay RR
    Clin Genitourin Cancer; 2023 Feb; 21(1):55-62. PubMed ID: 36411184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
    Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
    Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
    Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
    J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
    Ross JA; Miller M; Hernandez CR
    Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
    Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
    J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
    Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.